Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation
Genetics

Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation

Modified aminoglycoside compounds neutralize a key enzyme that strips away protective sugar coatings and triggers cell death in human pancreatic islets.

By Faisal Qureshi
Published:
Email this Article
Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation
Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Synthetic molecules derived from an old antibiotic can protect delicate insulin-producing cells from destructive inflammation and oxidative damage, offering fresh hope for diabetes intervention. The research, published in ACS Pharmacology & Translational Science, demonstrates that targeting a specific enzyme involved in tissue degradation can interrupt the cascading cellular injury characteristic of early diabetes progression.

How an Enzyme Drives Inflammation and Cell Damage

During the onset of type 1 diabetes, pancreatic beta-cells face a relentless onslaught from the immune system. Beyond direct autoimmune attacks, specialized immune cells called macrophages infiltrate the pancreas and release an enzyme known as heparanase, or HPSE. This enzyme normally chews up heparan sulfate, a protective sugar coating that maintains the structural integrity of the extracellular matrix surrounding insulin-producing cell clusters known as islets. When heparanase strips away this protective coating, it triggers a destructive cycle of inflammation, oxidative stress, and eventual cell death.

To combat this pathway, a team of researchers led by scientists at Wayne State University developed two specialized drug candidates named L15 and L17. These compounds act as artificial mimetics of the body’s natural sugar chains, binding directly to heparanase and blocking its destructive enzymatic activity. Unlike older experimental drugs that required dozens of complicated chemical steps to manufacture, these new aminoglycoside derivatives can be synthesized far more efficiently, making them practical candidates for therapeutic development.

1: Proposed mechanisms of HPSE-mediated β-cell injury and therapeutic intervention by aminoglycoside-derived inhibitors L15 and L17. (A) Inflammatory stimuli promote macrophage polarization from the quiescent M0 phenotype to the pro-inflammatory M1 phenotype, leading to increased secretion of heparanase (HPSE), proinflammatory cytokines (e.g., IL-1β, TNF-α, IL-6), and reactive oxygen species (ROS), thereby establishing a positive feedback loop that amplifies inflammation. (B) HPSE degrades heparan sulfate (HS) and disrupts the basement membrane (BM), resulting in loss of extracellular matrix integrity and facilitating immune cell infiltration into pancreatic islets. (C) Loss of HS and increased oxidative stress induce mitochondrial dysfunction, elevated ROS production, DNA damage, and apoptosis in β-cells, ultimately leading to impaired insulin secretion and β-cell dysfunction. (D) L15 and L17 inhibit HPSE activity, thereby suppressing macrophage polarization, preserving HS integrity and
Proposed mechanisms of HPSE-mediated β-cell injury and therapeutic intervention by aminoglycoside-derived inhibitors L15 and L17. (A) Inflammatory stimuli promote macrophage polarization from the quiescent M0 phenotype to the pro-inflammatory M1 phenotype, leading to increased secretion of heparanase (HPSE), proinflammatory cytokines (e.g., IL-1β, TNF-α, IL-6), and reactive oxygen species (ROS), thereby establishing a positive feedback loop that amplifies inflammation. (B) HPSE degrades heparan sulfate (HS) and disrupts the basement membrane (BM), resulting in loss of extracellular matrix integrity and facilitating immune cell infiltration into pancreatic islets. (C) Loss of HS and increased oxidative stress induce mitochondrial dysfunction, elevated ROS production, DNA damage, and apoptosis in β-cells, ultimately leading to impaired insulin secretion and β-cell dysfunction. (D) L15 and L17 inhibit HPSE activity, thereby suppressing macrophage polarization, preserving HS integrity and Credit: Junzhe Wang et al. / ACS pharmacology & translational science

What Happens When Inhibitors Block the Damage Cascade

In laboratory experiments using mouse macrophages, pretreating the cells with L15 or L17 significantly suppressed the activation of pro-inflammatory immune pathways. The treatments dramatically reduced the expression of inflammatory markers like inducible nitric oxide synthase and key signaling proteins including tumor necrosis factor alpha and interleukin-6. When these treated immune secretions were applied to pancreatic beta-cell models, the protective compounds successfully preserved cell viability and prevented the structural collapse typically caused by inflammatory stress.

Further microscopic analysis revealed the precise timeline of cellular destruction. The team discovered that mitochondrial oxidative stress, marked by a surge in reactive oxygen species, begins as early as 8 hours after exposure to inflammatory triggers. This oxidative stress acts as an upstream driver that subsequently ruins the cellular cytoskeleton by dismantling F-actin networks before finally inducing programmed cell death 24 hours later. By introducing the antioxidant N-acetylcysteine or applying the heparanase inhibitors L15 and L17, the researchers successfully halted this destructive chain reaction.

Protecting Human Islets Ex Vivo

To verify whether these laboratory findings translate to human biology, the investigators tested the compounds on human pancreatic islets obtained from cadaveric donors. When untreated human islets were exposed to heparanase and inflammatory cytokines, they suffered a near-complete loss of their protective heparan sulfate coating, experienced massive oxidative stress, and lost their ability to secrete insulin in response to changing glucose levels.

2: Evaluation of cytotoxicity of L15 and L17 in MIN6 cells. (A). Dose-dependent cytotoxicity of L15 and L17 in MIN6 cells. (B). Time-dependent cytotoxicity of L15 and L17 at 60 μM in MIN6 cells. Data are presented as mean ± SEM from three independent experiments.
Evaluation of cytotoxicity of L15 and L17 in MIN6 cells. (A). Dose-dependent cytotoxicity of L15 and L17 in MIN6 cells. (B). Time-dependent cytotoxicity of L15 and L17 at 60 μM in MIN6 cells. Data are presented as mean ± SEM from three independent experiments. Credit: Junzhe Wang et al. / ACS pharmacology & translational science

Can L17 Restore Normal Insulin Secretion?

When human islets were treated with compound L15 or L17 alongside inflammatory triggers, the results were strikingly positive. Both molecules preserved the delicate heparan sulfate coating and suppressed total reactive oxygen species. Compound L17 proved particularly potent, consistently restoring glucose-stimulated insulin secretion to levels closely matching healthy, untreated control islets. These findings suggest that blocking heparanase shields human tissue from inflammatory degradation and maintains vital metabolic functions under stress.

While these initial ex vivo results mark an encouraging step forward, the authors note that further validation in living animal models of diabetes, such as mice treated with streptozotocin or non-obese diabetic strains, will be essential. Future studies will determine whether these protective mechanisms translate into sustained glycemic control and delayed disease progression in whole organisms.

The research was published in ACS pharmacology & translational science on October 5, 2026.

Fact Checked

This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.

Last reviewed on .

Article history

  • Latest version

Reference(s)

  1. Wang, Junzhe., et al. “Heparanase-Inhibiting Glycans Protect Pancreatic β-Cells from Oxidative and Inflammatory Injuries and Preserve Insulin Production in Human Islets.” ACS Pharmacology & Translational Science, vol. 9, no. 11, October 5, 2026, pp. 3203-3216. American Chemical Society (ACS), doi: 10.1021/acsptsci.6c00370. <https://doi.org/10.1021/acsptsci.6c00370>.

Cite this page:

Qureshi, Faisal. “Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation.” BioScience. BioScience ISSN 2521-5760, 20 November 2026. <https://www.bioscience.com.pk/en/subject/genetics/heparanase-inhibiting-glycans-protect-pancreatic-b-cells-from-oxidative-and-inflammatory-injuries-and-preserve-insulin-production-in-human-islets>. Qureshi, F. (2026, November 20). “Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation.” BioScience. ISSN 2521-5760. Retrieved November 20, 2026 from https://www.bioscience.com.pk/en/subject/genetics/heparanase-inhibiting-glycans-protect-pancreatic-b-cells-from-oxidative-and-inflammatory-injuries-and-preserve-insulin-production-in-human-islets Qureshi, Faisal. “Novel Glycans Shield Insulin-Secreting Cells From Destructive Diabetes Inflammation.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/subject/genetics/heparanase-inhibiting-glycans-protect-pancreatic-b-cells-from-oxidative-and-inflammatory-injuries-and-preserve-insulin-production-in-human-islets (accessed November 20, 2026).
End of the article